Company Overview of Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. researches, develops, and manufactures pharmaceuticals worldwide. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007 Abraxane, a human serum albumin-bound paclitaxel; TSU-68, a multiple receptor tyrosine kinase inhibitor; TAS-102, an antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance extracted from the colonial tunicate ecteinascidia turbinata. Its products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS-115, an ATP-competitive small molecule inhibitor of c-Met and VEGFR; TAS-116, a potent or...
Founded in 1963
Key Executives for Taiho Pharmaceutical Co., Ltd.
President and Representative Director
CEO of Otsuka Holdings Co., Ltd., President & Representative Director of Otsuka Holdings Co., Ltd.
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2017.
Taiho Pharmaceutical Co., Ltd. Key Developments
Taiho Pharmaceutical Co., Ltd. Establishes Taiho Pharma Canada, Inc
Mar 7 17
Taiho Pharmaceutical Co., Ltd. announced on March 7, 2017, that it has established its subsidiary Taiho Pharma Canada Inc. in Oakville, Ontario. The Canadian operations will be managed by Taiho Oncology Inc., the U.S. R&D and commercial operations of the Taiho Group, based in Princeton, N.J.
Taiho Pharmaceutical Releases Pure Quick S Ointment, a New Mini Size Steroid Product
Feb 7 17
Taiho Pharmaceutical Co., Ltd. announced that it has launched Pure Quick S Ointment (designated secondclass OTC drug) nationwide in Japan February 7, 2017. Pure Quick S Ointment, a 2gram steroid ointment that is a good amount to use up. Pure Quick S Ointment was developed based on feedback that women want to heal and condition their skin quickly, then they can enjoy making up and dressing up in a matter of time. The product focuses on delivering convenience as well as effectiveness. Pure Quick S Ointment meets the need for an ointment in a size that customers will find easy to carry around and use up without wasting any, thereby keeping up a positive frame of mind on skincare. An antedrug is a drug that has an effect at the site of application but changes into a substance with low activity inside the body. Pure Quick S Ointment is provided in a compact size that it easy for one person to use up without waste.
X-Chem, Inc. Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical Using DEX Technology
Dec 20 16
X-Chem, Inc. announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in multiple therapeutic areas with unmet medical need. Under the terms of this new agreement, X-Chem will receive an up-front payment as well as potential pre-clinical, clinical and regulatory milestone payments and sales milestones, up to a total of $352 million. Taiho has an exclusive option to license any programs generated in the course of the collaboration. X-Chem will also receive royalties for each successfully commercialized drug that results from a licensed collaboration program.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|